A randomised multicentre phase III prospective open-label trial of pre-operative bevacizumab (Avastin) in combination with neo-adjuvant chemotherapy for early breast cancer patients

Trial Profile

A randomised multicentre phase III prospective open-label trial of pre-operative bevacizumab (Avastin) in combination with neo-adjuvant chemotherapy for early breast cancer patients

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Cyclophosphamide; Docetaxel; Epirubicin; Fluorouracil
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Acronyms ARTemis
  • Most Recent Events

    • 27 Apr 2017 Results assessing disease-free and overall survival at 3.5 years, published in the Annals of Oncology
    • 07 Jun 2016 Results assessing the disease-free survival and overall survival in female patients with HER2 negative early breast cancer presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 06 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ISRCTN: Current Controlled Trials record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top